Today, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) convenes to discuss Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application (NDA).The meeting, which is scheduled to run from 8:30AM – 5:30PM ET, will feature presentations from both FDA and Lykos, as well as public comments. At the end of the meeting, PDAC members will vote on two questions. While their votes are…
